| Title |
Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012
|
|---|---|
| Published in |
Drug Safety, July 2013
|
| DOI | 10.1007/s40264-013-0084-0 |
| Pubmed ID | |
| Authors |
Sheena N. Ramasamy, Cameron S. Korb-Wells, Diluk R. W. Kannangara, Myles W. H. Smith, Nan Wang, Darren M. Roberts, Garry G. Graham, Kenneth M. Williams, Richard O. Day |
| Abstract |
Allopurinol is the primary therapy for the management of chronic gout. Utilization of allopurinol has increased in tandem with the growing prevalence of gout globally. This exposes more patients to the risk of allopurinol hypersensitivity (AH), a rare adverse reaction characterised by a spectrum of cutaneous reactions and systemic manifestations. Severe forms of AH have been associated with high mortality. The pathophysiology underlying this reaction remains unknown, but several risk factors have been proposed. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 50% |
| Grenada | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Poland | 1 | <1% |
| Unknown | 101 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 15% |
| Researcher | 14 | 14% |
| Student > Postgraduate | 11 | 11% |
| Student > Master | 10 | 10% |
| Student > Ph. D. Student | 8 | 8% |
| Other | 25 | 25% |
| Unknown | 19 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 46% |
| Agricultural and Biological Sciences | 9 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 6% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Chemistry | 3 | 3% |
| Other | 6 | 6% |
| Unknown | 26 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2023.
All research outputs
#1,466,237
of 25,045,181 outputs
Outputs from Drug Safety
#135
of 1,797 outputs
Outputs of similar age
#12,244
of 203,491 outputs
Outputs of similar age from Drug Safety
#3
of 16 outputs
Altmetric has tracked 25,045,181 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,797 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 203,491 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.